Sunday, September 03, 2023 6:00:59 PM
I wonder if Robin Hood will take OTC orders on the phone, but not on line. If not, I'd either move my account, or part of it, to someone like Fidelity. They have no charges for OTC transactions and it costs nothing to get an account.
Remember NWBO's not a Pink, though I believe Fidelity permits those as well, the OTC is a step above that. At $1 they probably could move on to the AMEX, but I don't believe they want it, though it's a step above the OTC.
If they reach the $5 area I believe they'll go for the NYSE. They were on the Nasdaq before and while they probably could get back on at $2, LP I understand wants the NYSE and no telling, when we hit $2 we might make $5 shortly after that, it all depends on the news that gets us there.
I frankly don't believe that LP would take on an equity partnership with a BP for over 1% of the company for under $10 a share. Any such announcement would almost immediately take our share price to near what a BP was willing to pay, and the BP's know it. They might get some flack from their shareholders if they paid $10 when we were $2 or less, but as the story of what the company has going came out, the shareholders would be satisfied if they bought a far bigger position for far more.
I certainly don't know that this will happen, but believe our story is compelling and if the BP's validate it with a partnership, our market cap ought to be in double digit billions.
Gary
Remember NWBO's not a Pink, though I believe Fidelity permits those as well, the OTC is a step above that. At $1 they probably could move on to the AMEX, but I don't believe they want it, though it's a step above the OTC.
If they reach the $5 area I believe they'll go for the NYSE. They were on the Nasdaq before and while they probably could get back on at $2, LP I understand wants the NYSE and no telling, when we hit $2 we might make $5 shortly after that, it all depends on the news that gets us there.
I frankly don't believe that LP would take on an equity partnership with a BP for over 1% of the company for under $10 a share. Any such announcement would almost immediately take our share price to near what a BP was willing to pay, and the BP's know it. They might get some flack from their shareholders if they paid $10 when we were $2 or less, but as the story of what the company has going came out, the shareholders would be satisfied if they bought a far bigger position for far more.
I certainly don't know that this will happen, but believe our story is compelling and if the BP's validate it with a partnership, our market cap ought to be in double digit billions.
Gary
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
